What happened with MMED today?
No read yet
Uses news and trading volume to explain the day’s move and how it relates to the market.
Stop guessing. Get the call, a three-month target price, the best and worst cases, and a source for every claim.
MiniMed Group serves people with type 1 diabetes and those with type 2 diabetes who need intensive insulin therapy. Its MiniMed 780G system combines an insulin pump, a continuous glucose sensor and SmartGuard software, which uses sensor readings to adjust insulin delivery automatically. For people who inject insulin rather than use a pump, MiniMed Go combines the InPen smart insulin pen with glucose monitoring and an app.
Customers buy pumps or pens, then regularly replace sensors and insulin-delivery supplies to keep using the systems. Those repeat purchases generate most of MiniMed’s revenue, with glucose monitoring its largest sales category. It sells to patients, distributors, healthcare providers and institutions. Most customers rely on private insurance or government healthcare coverage to support purchases. Most revenue comes from outside the United States; U.S. distribution mainly uses the durable medical equipment channel rather than pharmacies.
The business depends on retaining users and maintaining reimbursement and supply. Abbott exclusively supplies third-party glucose sensors for certain systems, and the agreement restricts MiniMed from buying or distributing sensors from certain Abbott competitors. Convatec is its sole infusion-set supplier. Products and changes need regulatory authorization, and MiniMed may promote devices only within their approved labeling.
The risk section is the longest, dullest part of the filing. This keeps only what can really hurt you: where it hits, how hard, when it plays out.
Every company claims an edge. Each one is checked against hard numbers like margins and returns: which hold, and which line gives way first.
With roughly 70% of revenue outside the United States, MiniMed depends on winning and keeping pump users against international rivals including mylife Diabetes Care and Medtrum.
Tandem Diabetes Care and MiniMed compete for much the same patients needing intensive insulin therapy in U.S. and international markets, selling long-lived automated insulin pumps and supplies patients replace regularly. Watch Tandem’s t:slim X2 and Mobi pump sales: winning users also brings repeat cartridge and infusion-set business.
Insulet’s Omnipod competes with MiniMed’s automated insulin-delivery systems for insulin-dependent patients, and MiniMed’s planned Fit patch pump targets Omnipod’s tubeless, body-worn format. Watch Omnipod adoption as MiniMed prepares to enter that format, where patients repeatedly replace disposable insulin-delivery Pods.
Dexcom and MiniMed compete to sell sensors that continuously track glucose to people managing diabetes, so sensor uptake and pricing matter to both. Watch Dexcom’s sensor sales and pricing against MiniMed’s CGM revenue, its largest product category in the fiscal year ended April 24, 2026.
Abbott both competes with MiniMed through Libre glucose sensors and supplies the third-party sensors used in certain MiniMed automated-delivery and smart-pen systems, with MiniMed paying Abbott per sensor. Watch that supply partnership, which also extends to sensors measuring both glucose and ketones for exclusive integration with MiniMed smart dosing systems.
Beta Bionics’ iLet competes with MiniMed’s automated insulin-delivery systems for U.S. type 1 diabetes patients, with orders typically paid by third-party payors directly or through distributors. Watch iLet user growth: its users must buy compatible cartridges and infusion sets rather than third-party alternatives, tying pump adoption to recurring supply sales.
Medtronic retained approximately 90% of MiniMed after its IPO and provides transition services, so the tie is ownership and separation costs, not independent competition in diabetes devices. Watch the cost of replacing those services: MiniMed’s historical allocated corporate costs may understate what it needs to spend to operate independently.
Abbott Laboratories earningsABT
Abbott’s report gives a read on the glucose-sensor supplier whose products MiniMed buys for some systems, though it cannot show MiniMed’s actual deliveries or prices.
Watch Abbott’s CGM sales and any comments on capacity or supply. Steady CGM sales without reported constraints would support the view that the supplier’s business is on a sound footing; weaker sales or disclosed constraints would highlight MiniMed’s reliance on an outside sensor supplier. Neither settles MiniMed’s actual supply or partnership costs.
DexCom, Inc. earningsDXCM
Dexcom’s report will show how sensor sales and pricing are changing in the CGM market, MiniMed’s largest product category.
Compare Dexcom’s reported CGM sales and pricing trends with MiniMed’s own CGM sales. Dexcom sales growth alongside pricing pressure would show a rival expanding in a market where prices are under strain, making conditions tougher for MiniMed’s CGM business. Weaker Dexcom sales without clear price pressure would suggest less competitive strain, but would not prove MiniMed is winning customers.
Insulet Corporation earningsPODD
Insulet’s Omnipod report will show patient uptake of tubeless, body-worn pumps, the format MiniMed is targeting with its planned Fit patch pump.
Read Omnipod user growth alongside sales of its disposable Pods. Strength in both would show patients are adopting the tubeless pump and continuing to buy its supplies; weakness in both would point to a less convincing demand signal. For MiniMed, this tests whether the market its planned Fit pump would enter has sustained demand, not whether Fit itself will succeed.
MiniMed Group, Inc. earningsThis company
CGMs and consumables make up most of MiniMed’s sales, but CGMs carry lower margins; this report will show whether growth in these recurring products is improving the business’s economics.
Read CGM and consumables sales growth alongside gross profit and operating loss. Growth in both sales categories with improving gross profit and a narrower operating loss would show that greater system use is translating into better economics. If growth comes mainly from lower-margin CGMs while gross profit weakens and the operating loss widens, sales growth is not yet improving the business’s economics.
